BioSpace News Archive

On December 15, 2020, Professor Wang Jian’an’s team from the Second Hospital of Zhejiang University School of Medicine successfully applied the DragonFly-T™ Transcatheter Tricuspid Valve Clamping System to perform the first human clinical application in mainland China.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has initiated a series of proof of concept (POC), in-vivo , animal model studies to test its drug candidate RCC-33 on mice tr

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion to recommend the conditional marketing authorization (CMA) of the Pfizer-BioNTech COVID-19 Vaccine (also known as BNT162b2), f

Life Sciences Investor Forum today announced that the presentations from the December 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive discussions focused on the life sciences industry. The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “vi

The funding round was spearheaded by US based Rhia Ventures, Astia angels and existing investors Pontifax VC to bring OCON’s first ever 3D long-term intrauterine contraceptive to the US market

Olympus announced today the first patient enrolled in an international study to collect real-world evidence on the performance of the new SOLTIVE ™ Premium SuperPulsed Laser System

exocad GmbH, an Align Technology, Inc. company, announced the availability of exoplan 3.0 Galway, the latest version of its implant planning software.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of a triple combination therapy with melflufen plus dexamethasone and subcutaneous daratumumab compared to daratumumab alone. The phase 3 LIGHTHOUSE study is a random

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE™) technology platform is pleased to announce the presentation of additional interim data results for the Company’s lead therapeutic candidate, GTB-3550, for the treat

Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health will join the University of Chicago Harris School of Public Policy on March 4 for a conversation hosted by its dean, Katherine Baicker, who will award Dr. Fauci the 2020 Harris Dean’s Award.